<DOC>
	<DOCNO>NCT01854749</DOCNO>
	<brief_summary>Assess efficacy safety S1 combine cisplatin treatment recurrence/metastasis ESCC</brief_summary>
	<brief_title>S1 Combined With Cisplatin Treatment Recurrence/Metastasis ESCC Open-label Single Center Phase II Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion Criteria Joined study voluntarily sign informed consent form ; Age 1875 .Presence least one index lesion measurable CT scan MRI recurrence/metastasis Esophageal carcinoma gastroesophageal cancer confirm pathology No radiotherapy , chemotherapy treatment prior enrollment PS ECOG 01 Life expectancy 3 month ANC≥2×109/L，PLT≥100×109/L，Hb≥90g/L Cr≤1.0×UNL TBIL≤1.25×UNL； ALT/AST≤2.5×UNL，with hepatic metastasis ALT/AST≤5.0×UNL；AKP≤2.5×UNL radical cure cancer uncontrolled chronic diarrhea esophageal obstruction Neurological mental abnormality Influence cognitive ability include central nervous system metastasis Severe complication ( ) , e.g. , uncontrolled active infection , myocardial infarction , hypertension , arrhythmia , stenocardia Patient metastasis except cured skin basal cell carcinoma carcinoma situ cervix accept antitumor therapy •Female patient pregnant lactation period , patient without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ESCC</keyword>
</DOC>